Company intelligence / Profile preview
HysensBio
Gwacheon-si, Gyeonggi-do, South Koreahysensbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
HysensBio’s lead program uses a novel 10-amino acid synthetic peptide derived from the CPNE7 protein to activate dental cells for regeneration of dentin and periodontal tissues. The lead product has shown promising results in phase 1/2a clinical studies for dentin hypersensitivity. The company’s approach aims to permanently restore natural tooth structure rather than provide temporary relief.
- Therapeutic areas
- Rare DiseasesInfectious DiseasesDermatologyOphthalmologyOther
- Modalities
- Synthetic peptideCell therapySmall molecule drug
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
No major pharmaceutical partnerships disclosed as of June 2025.
Beyond the preview
Go deeper on HysensBio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HysensBio.